Amediplase. Menarini.

Abstract	Amediplase, a chimeric protein containing functional domains of both tissue plasminogen activator and pro-urokinase plasminogen activator, is under development by Menarini for the potential treatment of thrombosis. Phase III trials with amediplase were underway by June 2002.
Authors	Sheila A Doggrell
Journal	Current opinion in investigational drugs (London, England : 2000) (Curr Opin Investig Drugs) Vol. 5 Issue 3 Pg. 344-7 (Mar 2004) ISSN: 1472-4472 [Print] England
PMID	15083603 (Publication Type: Journal Article, Review)
Chemical References	Fibrinolytic Agents Recombinant Proteins amediplase Tissue Plasminogen Activator Urokinase-Type Plasminogen Activator
Topics	Animals Clinical Trials, Phase I as Topic Fibrinolytic Agents (chemistry, pharmacokinetics, therapeutic use) Humans Recombinant Proteins Structure-Activity Relationship Thrombosis (drug therapy) Tissue Plasminogen Activator (chemistry, pharmacokinetics, therapeutic use) Urokinase-Type Plasminogen Activator (chemistry, pharmacokinetics, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!